Yhdysvallat - englanti - NLM (National Library of Medicine)

elanco us inc. - cyclosporine (unii: 83hn0gtj6d) (cyclosporine - unii:83hn0gtj6d) - cyclosporine 100 mg in 1 ml - do not use in cats with a history of malignant disorders or suspected malignancy. do not use in cats infected with feline leukemia virus (felv) or feline immunodeficiency virus (fiv). do not use in cats with a hypersensitivity to cyclosporine. instructions for assembling the dispensing system and preparing a dose of atopica ™ for cats (cyclosporine oral solution) usp modified assembling the dispensing system the dispensing system consists of 4 parts: - a bottle containing the medicine, with rubber stopper and a screw cap to close the bottle after use. - a plastic adapter with dip tube that you will push into the neck of the bottle. the adapter must always remain in the bottle after first use. - an oral dosing syringe that fits into the top of the plastic adapter to withdraw the prescribed dose of medicine from the bottle. - a plastic vial containing the plastic adapter and oral dosing syringe. save the plastic vial to store the oral dosing syringe between each use. fitting the plastic adapter into the new b

Yhdysvallat - englanti - NLM (National Library of Medicine)

stat rx usa llc - cyclobenzaprine hydrochloride (unii: 0ve05jys2p) (cyclobenzaprine - unii:69o5wqq5ti) - cyclobenzaprine 15 mg - amrix is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, and limitation of motion. amrix should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. amrix has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease or in children with cerebral palsy. - hypersensitivity to any component of this product. - concomitant use of monoamine oxidase (mao) inhibitors or within 14 days after their discontinuation. - hyperpyretic crisis seizures and deaths have occurred in patients receiving cyclobenz

Yhdysvallat - englanti - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj), neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k) - hydrocortisone 10 mg in 1 ml - for the treatment of superficial bacterial infections of the external auditory canal caused by organisms susceptible to the action of the antibiotics, and for the treatment of infections of mastoidectomy and fenestration cavities caused by organisms susceptible to the antibiotics. this product is contraindicated in those individuals who have shown hypersensitivity to any of its components, and in herpes simplex, vaccinia, and varicella infections.

Yhdysvallat - englanti - NLM (National Library of Medicine)

bausch & lomb incorporated - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - neomycin 3.5 mg in 1 g - for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular anti-infective drug in this product is active against the following common bacterial eye pathogens: staphylococcus aureus, escherichia coli, haemophilus influenzae, klebsiella/enterobacter

Yhdysvallat - englanti - NLM (National Library of Medicine)

bausch & lomb incorporated - hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj), neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k) - hydrocortisone 10 mg in 1 ml - for the treatment of superficial bacterial infections of the external auditory canal caused by organisms susceptible to the action of the antibiotics, and for the treatment of infections of mastoidectomy and fenestration cavities caused by organisms susceptible to the antibiotics. this product is contraindicated in those individuals who have shown hypersensitivity to any of its components, and in herpes simplex, vaccinia, and varicella infections.

Yhdysvallat - englanti - NLM (National Library of Medicine)

bausch & lomb incorporated - bacitracin zinc (unii: 89y4m234es) (bacitracin - unii:58h6rwo52i), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k) - bacitracin 500 [usp'u] in 1 g - for the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to bacitracin zinc and polymyxin b sulfate. this product is contraindicated in those individuals who have shown hypersensitivity to any of its components.

Yhdysvallat - englanti - NLM (National Library of Medicine)

bausch & lomb incorporated - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), bacitracin zinc (unii: 89y4m234es) (bacitracin - unii:58h6rwo52i), hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - neomycin 3.5 mg in 1 g - neomycin and polymyxin b sulfates, bacitracin zinc and hydrocortisone ophthalmic ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye (see clinical pharmacology , microbiology ). the particular anti-infective drugs in this produc

Yhdysvallat - englanti - NLM (National Library of Medicine)

bausch & lomb incorporated - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - neomycin 3.5 mg in 1 ml - for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroids use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular anti-infective drug in this product is active against the following common bacterial eye pathogens: staphylococcus aureus, escherichia coli , haemophilus influenzae, klebsiella/enter

Yhdysvallat - englanti - NLM (National Library of Medicine)

bausch & lomb incorporated - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), bacitracin zinc (unii: 89y4m234es) (bacitracin - unii:58h6rwo52i) - neomycin 3.5 mg in 1 g - neomycin and polymyxin b sulfates and bacitracin zinc ophthalmic ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis. neomycin and polymyxin b sulfates and bacitracin zinc ophthalmic ointment is contraindicated in individuals who have shown hypersensitivity to any of its components.

Yhdysvallat - englanti - NLM (National Library of Medicine)

bausch & lomb incorporated - polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), trimethoprim sulfate (unii: e377mf8eq8) (trimethoprim - unii:an164j8y0x) - polymyxin b 10000 [usp'u] in 1 ml - polymyxin b sulfate and trimethoprim ophthalmic solution is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following microorganisms: staphylococcus aureus, staphylococcus epidermidis, streptococcus pneumoniae, streptococcus viridans, haemophilus influenzae and pseudomonas aeruginosa. 1 1 efficacy for this organism in this organ system was studied in fewer than 10 infections. polymyxin b sulfate and trimethoprim ophthalmic solution is contraindicated in patients with known hypersensitivity to any of its components.